Tuesday’s earnings report will show whether record Q3 production translates into cash for shareholders under Lula’s new term, or gets redirected elsewhere.
With ING auctioning $500 million of data-center loans and $38 billion of Oracle-linked debt still circulating, Monday’s numbers set the tone for every alternatives manager that follows.
NATO’s 5% of GDP by 2035 means the spending floor has moved.
Union Pacific’s autonomous inspection fleet has logged 500,000 track miles a year. The question for Thursday’s Q3 release is whether that translates into a sustainably lower operating ratio.
Orchestra Bio puts IQV, VEEV, and CRL in the crosshairs.
With personal-injury claims still unresolved and the Solventum stake swinging reported earnings, income investors need to look past the headline number today.
Saturday’s 550,000-person protest is the backdrop. Monday’s bonds are the verdict.
Thoma Bravo’s $6.3 billion all-cash bid for Varonis says something specific about where buyers think AI-era data security is undervalued.
The bank’s exit from US and European primary dealing raises a harder question: who fills the gap when government debt is this hard to sell?
Fewer plan choices open Oct. 15, and Humana’s star surge is moving stocks.
